← Human Trials & Peer-Reviewed Studies
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Plain-language guide to PMID 35578182 (2022): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide), migraine.
Key Facts
- PMID
- 35578182
- Journal
- The journal of headache and pain
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Driessen MT et al. (11 authors)
- DOI
- 10.1186/s10194-022-01415-x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.
Who Took Part
By PubMed's age tags, the people studied were teenagers and adults.
These endpoints were evaluated in subgroups of patients by migraine type (EM/CM) and in subgroups with DTT migraine (diagnosis of medication overuse [MO], major depressive disorder [MDD], generalized anxiety disorder [GAD], or prior exposure to a different CGRP pathway-targeted mAb [CGRP mAb]).
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.
As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.
This retrospective, panel-based online chart review used electronic case report forms.
Changes in MMD and monthly headache days were assessed during the follow-up period.
What Was Measured
PubMed files the paper under topics including Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Major Depressive Disorder and Migraine Disorders.
The authors tagged it with the keywords CGRP, Chart review, Difficult-to-treat, Fremanezumab, Migraine preventive treatment and Real-world effectiveness.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (The journal of headache and pain), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.